The slimming elixir is on sale! Novo Nordisk raised its annual operating profit growth by at least 40%
安全到达彼岸依
发表于 2023-10-14 06:35:17
1322
0
0
On October 13th local time, the official website of Novo Nordisk (NVO.US) announced that based on a fixed exchange rate (CER), sales for the first nine months of 2023 increased by 33% year-on-year, and operating profit increased by 37% year-on-year. In addition, the company has raised its annual sales and operating profit expectations, with sales expected to increase by 32% to 38% and operating profit expected to increase by 40% to 46%. Previously, the expected sales growth was 27% to 33%, while operating profit growth was 31% to 37%.
Novo Nordisk stated that the updated performance for 2023 mainly reflects higher expectations for Ozenpic's full year sales in the United States, as well as adjustments to Ozenpic and Wegovy's net sales in the United States. Ozempic is Smeglutide, a GLP-1 drug under Novo Nordisk. This name is the English trade name of the drug's diabetes indication, and Wegovy is the English trade name of Smeglutide's weight loss indication. Elon Musk, CEO of Tesla, used the latter to lose weight, which was later regarded by some people as a "magic drug for weight loss".
Novo Nordisk's official website in China shows that the company's history can be traced back to 1923, and its headquarter is located in Copenhagen, the capital of Denmark. Its business covers diabetes, obesity, rare blood diseases, endocrine disorders and other diseases. Before GLP-1 drugs, Novo Nordisk was known for insulin and was recognized as one of the global insulin giants.
With GLP-1 class drugs, Novo Nordisk has achieved high performance. According to the financial report, the sales revenue of Smeglutide weight loss indications in 2022 was 6.188 billion Danish kroner, a year-on-year increase of 346%. According to Novo Nordisk's 2023 semi-annual report, the sales of Smeglutide weight loss indications were 12.081 billion Danish kroner (approximately 1.781 billion US dollars), a year-on-year increase of 367%. Novo Nordisk is expected to release its results for the first nine months on November 2nd.
In addition to diabetes and weight loss, smeglutide has the potential to expand its indications. On October 10 local time, Novo Nordisk announced the early termination of FLOW, a phase III clinical study of Smeglutide in the treatment of patients with type 2 diabetes mellitus complicated with renal insufficiency and chronic kidney disease, because the Independent Data Monitoring Committee (IDMC) analyzed the interim data, and the efficacy of the drug has reached specific preset standards. Earlier, Novo Nordisk also mentioned the effectiveness of smeagllutide in preventing major adverse cardiovascular events.
It is worth noting that Smeglutide is also facing safety tests. For example, the European Union Drug Administration (EMA) has said that it is investigating two drugs under Novo Nordisk, including Ozempic, a GLP-1 diabetes drug, and Saxenda, another GLP-1 weight loss drug.
In the secondary market, Novo Nordisk's stock price has also been steadily rising. On September 1st, according to foreign media reports, Novo Nordisk ended its two and a half year long ranking at the top of luxury goods manufacturer LVMUY. US, becoming the company with the highest market value in Europe. On October 12th, Novo Nordisk's stock price reached a new high, and as of the close of the day, it was at $100.18 per share, up 1.36%. After the US stock market opened on October 13th, Novo Nordisk continued to rise, rising by over 2% as of press release, with a market value exceeding $457.1 billion.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Bilibili Chen Rui: It is expected that adjusted operating profits will turn positive in the third quarter of this year
- Alaska Airlines claims that the suspension of 737 Max 9 flights may affect the company's long-term profit growth
- Witness history! Half Bitcoin! Decline in revenue? Miners are busy hoarding coins
- Exceeding expectations! Pinduoduo's revenue doubled year-on-year in the first quarter, and its operating profit increased nearly threefold
- Dell Technology's post market stock price fell by more than 18%. After adjusting for the first quarter, operating profit fell short of expectations
- Tesla Q2 profit falls short of expectations, Robotaxi postponed release to October, stock price drops by over 8% after hours
- Novo Nordisk's European stock fell 6.5%
- Observation of Cultural and Tourism Financial Report | "Ten Thousand Stores" Target Achieved, Huazhu Group's Revenue Increased by 14% in the First Half of the Year, Profit Approaching 2019
- Baidu Q2 financial report released, core profit growth exceeded expectations by 23%, AI driven high-quality business growth
- OpenAI reportedly considers changing company structure or removing profit caps for investors
-
AP通信9月27日、インテルは今月中旬に発表された重大な業務調整に加え、近日中にクアルコムに買収合併される可能性があるとの情報を伝えていることを明らかにした。 しかし、ウォール街のほとんどのアナリストは、 ...
- 什么大师特
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
9月27日、ネット通信社武漢グローバル本社の操業停止による荒廃について、同社の公式対応インタフェースニュースによると、同社本社の建設は操業停止ではなく、現在建設作業は計画通り着実に進められており、この1 ...
- 一念之间323
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
Alphabet傘下のグーグルの最新情報によると、同社は米国サウスカロライナ州に33億ドルを投資し、データセンターとクラウドインフラストラクチャを拡張する計画だ。 グーグルのサンダル・ピチャイ最高経営責任者は木 ...
- SNT
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 前天 18:03
- 支持
- 反对
- 回复
- 收藏